&nbsp;

dapProstateJuly18.xml

Jul 2018

Document

dapProstateJuly18.html

Jul 2018

Regimen

MFOLFOX6

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Guidelines and Advice

Safety Considerations for the Implementation of Subcutaneous Rituximab Formulation

Status: Current
Version: 1

Jun 2018

Regimen

NIVL+IPIL

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2025

Regimen

NIVL(MNT)

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

CABO

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

cabozantinib - For the treatment of advanced renal cell carcinoma (RCC), based on criteria

Drugs Used:

cabozantinib (tablet)

Quick Link(s):

Regimen Monograph

Dec 2024

Regimen

GEMC(RT)

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Adjuvant, Curative

Drugs Used:

gemcitabine

Quick Link(s):

Regimen Monograph

May 2019

Drug

olaparib

Other Name(s): Lynparza®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jan 2025

Document

ocp5-homepage-hero.jpg

Jul 2018

Document

ocp5LogoHeroOverlay.png

Jul 2018

Document